INC ResearchLLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process? for delivering reliable results, today announced it has attained four new accreditations in the Medidata Clinical Cloud?, further reinforcing its focus on innovation to help biopharmaceutical companies overcome critical cost, risk and efficiency challenges across the clinical chain.
INC Research LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced it has attained four new accreditations in the Medidata Clinical Cloud™, further reinforcing its focus on innovation to help biopharmaceutical companies overcome critical cost, risk and efficiency challenges across the clinical chain. With new accreditations in Medidata Designer®, Medidata Grants Manager®, Medidata CTMS™ and Medidata Rave® Safety Gateway, INC Research becomes the most highly accredited Medidata Services Partner and the first Company to achieve all available accreditations in the Medidata platform.
“INC Research’s therapeutic focus and process expertise along with Medidata’s innovative cloud-based clinical research platform provide a winning combination to streamline clinical development for our biopharmaceutical customers,” said Alistair Macdonald, Chief Operating Officer. “By leveraging Medidata’s cloud-based clinical research platform along with our own Trusted Process® methodology, INC can deliver time and cost-efficient methods that accelerate clinical development and optimize trials of every scope and scale from protocol design all the way through to database lock.”
With accreditation in Medidata Designer, INC Research is combining its long‑standing therapeutic expertise and commitment to operational excellence with leading-edge technologies to ensure each protocol is as focused and streamlined as possible to drive efficiencies and reduce associated drug development costs. By leveraging Medidata’s Grants Manager and CTMS applications, the Company is able to deliver more efficient site payments and monitoring visit reporting, while offering increased visibility into trial milestones. Using the Medidata Rave Safety Gateway, INC Research can now automate sponsors’ EDC-to-safety-system data transfers to expedite case triage, improving the accuracy of serious adverse event (SAE) case data and reducing data reconciliation activities to eliminate error-prone phone, paper and fax processes.
“As one of the first CROs to join the Medidata Partner Program, INC Research’s extraordinary familiarity and expertise is well known when it comes to leveraging the Medidata platform,” said Steve Heath, Vice President of Channel Sales at Medidata Solutions. “By becoming one of the first partners to achieve accreditations for Medidata CTMS, Grants Manager and Rave Safety Gateway and the first CRO to become accredited in Medidata's platform for all currently available accreditations, INC Research demonstrates once again why it is a leader in applying its clinical expertise and capabilities with best-in-class cloud-based technologies.”
In 2006, INC Research became one of the first CROs to join the Medidata Partner Program. The Company achieved its first Medidata accreditation in 2007 for Medidata Rave, an electronic data capture (EDC) and clinical data management (CDM) system, and since that time has conducted more than 160 study-builds using this tool. In May 2012, INC attained three additional accreditations, including Medidata Balance™, Rave Targeted SDV and Medidata Coder®. With its four newest accreditations, INC Research holds more accreditations than any other Medidata Services Partner.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.